ARTIDIS AG is a clinical-stage health-tech start-up founded in Basel, Switzerland that has developed the first atomic force microscopy device for cancer diagnosis and treatment optimization. The ARTIDIS nanotechnology platform integrates different types of clinical data
Job Description Summary #LI-Hybrid Internal job title: Director Location: Basel, Switzerland Translational Medicine Discovery & Profiling (TMDP) is a group of physicians and clinical researchers who drive innovative science from discovery to the patient through the selection,
About ARTIDIS ARTIDIS AG is a clinical-stage health-tech start-up founded in Basel, Switzerland, that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. The ARTIDIS nanotechnology platform integrates different types of clinical data
About ARTIDIS ARTIDIS AG is a clinical-stage health-tech start-up founded in Basel, Switzerland, that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. The ARTIDIS nanotechnology platform integrates different types of clinical data
About ARTIDIS ARTIDIS AG is a clinical-stage health-tech start-up founded in Basel, Switzerland that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. The ARTIDIS nanotechnology platform integrates different types of clinical data
About us GRANITE BIO is a private biotechnology company located in Basel (Switzerland). GRANITE BIO is supported by top-tier investors with ~$100M raised to date. Based on fundamental research conducted over the last two decades, GRANITE
About us GRANITE BIO is a private biotechnology company located in Basel (Switzerland). It is supported by top‑tier investors with approximately $100M raised to date. Building on fundamental research conducted over the last two decades, GRANITE
Clinical Development Lead Location: Allschwil, Basel Area, BL, CH The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&AQ pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)